Form 4: Director Bruce Booth Executes Kymera Stock Options

Director Bruce Booth exercised stock options and sold shares of Kymera Therapeutics under a pre-arranged 10b5-1 trading plan.

Summary

• Director Bruce Booth exercised options for 5,641 shares at $14.18 and 259 shares at $20.00.
• Following the exercise, 5,900 shares were sold at a weighted average price of $89.96.
• Additional sales of 100 shares were executed from indirect holdings (Atlas Venture funds) at $90.08.
• All transactions were conducted pursuant to Rule 10b5-1 trading plans adopted in December 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transactions were pre-planned and represent routine liquidity management by an insider.

Positives

• The director demonstrated confidence by holding significant indirect positions in the company through Atlas Venture funds.
• Transactions were executed via pre-planned 10b5-1 programs, indicating systematic rather than reactive selling.

Negatives

• The director reduced his direct beneficial ownership to zero following the exercise and sale of the acquired options.

Risks

• Future sales by the director or associated venture funds could impact market sentiment.
• Reliance on Rule 10b5-1 plans does not eliminate the potential for negative perception regarding insider selling.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that insider selling via 10b5-1 plans is a standard practice for directors and venture capital partners to realize gains on long-term equity compensation, and does not necessarily reflect a change in the company's fundamental outlook.

Comparison to Industry Standards

• The use of 10b5-1 plans is the industry standard for corporate insiders to avoid allegations of trading on material non-public information.
• The sale of shares following option exercise is consistent with typical executive compensation liquidity events in the biotechnology sector.

Related Party Transactions

• The reporting person is a member of Atlas Venture Associates X, LLC and Atlas Venture Associates Opportunity I, LLC, which manage funds holding Kymera shares.

Stakeholder Impact

• Minimal impact expected as the sales were conducted through pre-arranged trading plans.

Next Steps

• Monitor future Form 4 filings for additional sales by the reporting person or associated entities.

Key Dates

Keywords

Kymera Therapeutics, KYMR, Insider Trading, Form 4, Biotech, Stock Options, Atlas Venture